-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – T-3011 in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - T-3011 in Metastatic Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. T-3011 in Metastatic Colorectal Cancer Drug Details: T-3011 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – T-3011 in Malignant Ascites
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - T-3011 in Malignant Ascites report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. T-3011 in Malignant Ascites Drug Details: T-3011 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – T-3011 in Cutaneous Squamous Cell Carcinoma (cSCC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - T-3011 in Cutaneous Squamous Cell Carcinoma (cSCC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. T-3011 in Cutaneous Squamous Cell Carcinoma (cSCC) Drug...
-
Product Insights
Malignant Glioma – Drugs In Development, 2023
Global Markets Direct’s, ‘Malignant Glioma - Drugs In Development, 2023’, provides an overview of the Malignant Glioma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Malignant Glioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
High-Grade Glioma – Drugs In Development, 2023
Global Markets Direct’s, ‘High-Grade Glioma - Drugs In Development, 2023’, provides an overview of the High-Grade Glioma pipeline landscape. The report provides comprehensive information on the therapeutics under development for High-Grade Glioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Recurrent Head And Neck Cancer Squamous Cell Carcinoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Drugs In Development, 2023’, provides an overview of the Recurrent Head And Neck Cancer Squamous Cell Carcinoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the...
-
Product Insights
Recurrent Glioblastoma Multiforme (GBM) – Drugs In Development, 2023
Global Markets Direct’s, ‘Recurrent Glioblastoma Multiforme (GBM) - Drugs In Development, 2023’, provides an overview of the Recurrent Glioblastoma Multiforme (GBM) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Recurrent Glioblastoma Multiforme (GBM), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TQB-3395 in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TQB-3395 in Metastatic Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TQB-3395 in Metastatic Breast Cancer Drug Details: TQB-3395 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CIGB-128 in Brain Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CIGB-128 in Brain Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.CIGB-128 in Brain TumorDrug Details:CIGB-128 is under investigation for the treatment of Coronavirus...